AL

11C				
Notice of Allowability	Application No.	Applicant(s)		
	10/624,419	RICE ET AL.		
	Examiner	Art Unit		
	Evelyn Huang	1625		
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS (herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGOT (The Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apport or other appropriate communication GHTS. This application is subject to	olication. If not include will be mailed in due	ed course. THIS	
1. This communication is responsive to <u>response filed on 12-6-2004</u> .				
2. X The allowed claim(s) is/are 1,6-8 and 13.				
3. The drawings filed on are accepted by the Examiner.				
 4. Acknowledgment is made of a claim for foreign priority unitary. a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONMI 	been received. been received in Application No cuments have been received in this r of this communication to file a reply of	national stage applica		
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give	tted. Note the attached EXAMINER's		IOTICE OF	
 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 				
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.				
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. ☐ Notice of Informal Pa 6. ☑ Interview Summary (Paper No./Mail Date 7. ☑ Examiner's Amendm 8. ☑ Examiner's Statement 9. ☐ Other	(PTO-413), e nent/Comment	,	



Application/Control Number: 10/624,419

Art Unit: 1625

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Ersfeld on 3-2-2005. During the interview, the examiner suggested amending claim 1 by inserting 'carbocyclic' after 'R3 and R4 form a fused 5-7-membered saturated' for clarification purposes.

The application has been amended as follows:

Claim 1, definition of R3 and R4, after 'R3 and R4 form a fused 5-7-membered saturated', insert --carbocyclic--.

REASONS FOR ALLOWANCE

2. The following is an examiner's statement of reasons for allowance:

Claims 1, 6, 7, 8, 13 are allowed.

The amendment has obviated the 112 second paragraph rejection.

The 112 first paragraph rejection is withdrawn upon reconsideration in view of the amendment and Applicant's Remarks. The claims as amended are now commensurate in scope with the objective enablement.

Substituted dipyrromethenboron difluoride derivatives are described by Kang (5187288, 5274113, PTO-1449) and Haugland (5248782, PTO-1449) Lindstrom (5494916, PTO-1449) discloses the imidazo-pyridin-4-amine while Gerster (4949624, 4689338, PTO-1449) discloses the imidazoquinolin-4-amine. However, the instant dyed-labeled imidazo-pyridine fused to a 5-7-membered saturated carbocyclic ring is not taught or suggested by the prior art of record.

Application/Control Number: 10/624,419 Page 3

Art Unit: 1625

3. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Evelyn Huang whose telephone number is 571-272-0686. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Evelyn Huang Primary Examiner

Art Unit 1625